FULL DISCLOSURE: This content is sponsored by PharmaDrug Inc.
In this interview, David Kideckel, CEO of PharmaDrug (CSE: PHRX), discusses the company’s groundbreaking biosynthetic manufacturing method for pharmaceutical-grade cocaine. The focus is on addressing the fentanyl crisis and providing safe supply programs for overcoming illicit drug addiction. PharmaDrug aims to combat substance abuse through biosynthesis, ensuring consistent, pure, and cost-effective production of cocaine.
READ: Biosynthetic Cocaine? PharmaDrug Files Patent For Novel Manufacturing Method
David highlights the company’s history, his background, and potential markets, emphasizing harm reduction. The interview explores revenue opportunities, scalability, and ongoing regulatory efforts.
FULL DISCLOSURE: PharmaDrug is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of PharmaDrug. The author has been compensated to cover PharmaDrug on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
